Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This new course ran for the first time in January 2019, with an engaging and thought-provoking programme of talks, tours of facilities and group discussions. Feedback from participants was uniformly excellent. Applications for the January 2020 course open on 15th August 2019.

Landscape image of Oxford spires with hills in the backdrop.
Copyright © Oxford University Images / Greg Smolonski

The Oxford Short Course in Experimental Medicine for Mental Health (OxCEMM) provides a practical and comprehensive grounding in experimental medicine for mental health. It is aimed at those with a basic understanding, either at early stages in research, or planning to be actively involved in the future.

Are you aware of experimental medicine as an approach, but unsure how to begin your own study? Or are you supporting colleagues working on experimental medicine research projects, but unsure about the bigger picture?

The OxCEMM course is open to clinical and pre-clinical staff and trainees, and medical doctors at any career stage. It will be of interest to psychiatrists, neurologists, GPs and other specialists, nurses, basic scientists, allied health professionals and pharmacists.

 

OxCEMM 2020 promises to be an excellent opportunity to learn and improve skills and understanding of experimental medicine for mental health. Participants in the last course were engaged and enthusiastic. Even those who were already running experimental medicine studies said how much they had learnt and how useful it was to have all the practical information they need in a single place.

Associate Professor, Liz Tunbridge, NIHR Oxford Health Training Lead

There are limited places and bursaries available. Bursaries will cover the costs of the course, accommodation, evening/daytime meals, as well as, refreshments and they will be awarded by the NIHR Oxford Health Biomedical Research Centre.

 

Immensely useful. Thank you so much for organising an intellectually stimulating course filled with inspirational content and pragmatic advice.
OxCEMM 2019 participant.

 

 

 

 

 

 

 

 

 

For more information or to request an alert when applications open on 15th August for OxCEMM January 2020, please email tamara.lewin@psych.ox.ac.uk.

Read the course Brochure.

 

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

‘Thinking Family’ when an adult has a serious illness

New research shows that although patient’s family details were often recorded, this information was not routinely used to help patients share their diagnosis with children.

Treating mental illness with electricity - new podcast

A new wave of treatments that stimulate the brain with electricity are showing promise on patients and in clinical trials.

Hours of gaming not negatively impacting wellbeing of most adolescents - new study

University of Oxford researchers found that although many school-age adolescents are spending considerable time gaming, it is not having a negative impact on their wellbeing.

Few mental health apps make it to real world, according to new Oxford University study

Despite enthusiasm for digital technology in addressing young people’s mental health, few effective apps have been successfully rolled out.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Dementia research - new trial with diabetes drug

An important new trial will test the effects of oral semaglutide on the build-up of a protein in the brain that characterises Alzheimer's disease.